136 Results for "

CaV

" in MedChemExpress (MCE) Product Catalog:
Products (136)

136 Results for "CaV" in MCE Product Catalog:

Cat. No.: HY-P86337
Synonyms: CaV1; CaV; CaVeolin-1

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF, IP, ELISA

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-P82037A
Synonyms: CaV1; CaV; CaVeolin-1

Host:  

Rabbit

Application:  

WB, IHC-F, IHC-P, ICC/IF, IP

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-181612
COX-2/CaV2.2-IN-1 is an orally active and selective dual COX-2/CaV2.2 inhibitor, exhibiting a COX-2 IC50 of 0.26 μM and a CaV2.2 IC50 of 0.29 μM. COX-2/CaV2.2-IN-1 suppresses inflammatory responses and inflammatory mediator (IL-6, TNF-α, NO) production. COX-2/CaV2.2-IN-1 produces pronounced analgesic effects in diverse models of inflammatory, neuropathic, and visceral pain. COX-2/CaV2.2-IN-1 can be used for the research of chronic pain .
loading...
    loading...
Cat. No.: HY-RS26764
Research Areas:  

Others

Cav2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cav2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-115596
CAS No.: 2413939-96-3
Target:  

Calcium Channel

Research Areas:  

Neurological Disease

BTT-369 is a CaVα1·CaVβ3 protein-protein complex antagonist with a Ki of 2.0 μM. BTT-369 inhibits CaV2.2 currents, with an apparent IC50 value of 31 μM. BTT-369 disrupts the interaction between CaVα1 and CaVβ3 subunits. BTT-369 reduces the current density of CaV2.2, and shifts the voltage dependence of steady-state inactivation and activation of CaV2.2 to more positive potentials. BTT-369 alleviates mechanical hyperalgesia in a rat model of tibial nerve injury. BTT-369 can be used for the study of neuropathic pain .
loading...
    loading...
Cat. No.: HY-N21842
CAS No.: 80248-97-1
Vincapusine is an inhibitor of CaV3.1 calcium channel, with a IC50 of 11.83 μM against the human target. Vincapusine suppresses the functional activity of the CaV3.1 calcium channel. Vincapusine exerts antihypertensive activity by inhibiting the CaV3.1 calcium channel. Vincapusine is used in hypertension-related research .
loading...
    loading...
Cat. No.: HY-103309R
CAS No.: 1346233-68-8
Research Areas:  

Neurological Disease

ML218 (Standard) is the analytical standard of ML218 (HY-103309). This product is intended for research and analytical applications. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
loading...
    loading...
Cat. No.: HY-P10332
Target:  

Inhibitory Antibodies

Research Areas:  

Others

WL 47 dimer (ligand 1) is a caveolin-1 (CAV-1) ligand with high affinity, selectivity and oligomer dissociation activity. WL 47 dimer simultaneously occupies two binding sites of CAV-1, inducing the dissociation of oligomers. WL 47 dimer has 7500-fold improved affinity compared to its T20 parent ligand and an 80% decrease in sequence length. WL 47 dimer can be used to permit targeted study of CAV-1 function .
loading...
    loading...
Cat. No.: HY-175395
Onychocin B is a cyclic tetrapeptide isolated from Onychocola sclerotica. Onychocin B is a calcium channel blocker with an IC50 of 7.1 μM for Cav1.2 .
loading...
    loading...
Cat. No.: HY-P3269A
Target:  

Calcium Channel

Research Areas:  

Cardiovascular Disease

Calciseptine TFA, a polypeptide found in black mamba venom, is a selcetive Cav1.2 L-type calcium channel inhibitor with an IC50 of 92 nM. Calciseptine TFA binds to the pore domain shoulder at repeats III and IV of Cav1.2, stabilizing an inactivated conformation. Calciseptine TFA exhibits negative inotropic and negative relaxant effects on mice, and does not affect heart rate or the action potential of sinoatrial node pacemaker cells. Calciseptine TFA can be used for the research of cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-184190
ERG-IN-7 is a Nav1.5, Cav1.2 and Kv11.1 inhibitor with IC50 values of 10.34 μM, 21.01 μM, and 16.385 μM for human Nav1.5, Cav1.2, and Kv11.1, respectively. ERG-IN-7 prolongs action potentials, reduces conduction velocity, and restores cardiac function. ERG-IN-7 can be used for the research of ventricular arrhythmia .
loading...
    loading...
Cat. No.: HY-P811010
Synonyms: KIAA1123, CACNA1G, Voltage-dependent T-type calcium channel subunit alpha-1G, CaV3.1c, NBR13, Voltage-gated calcium channel subunit alpha CaV3.1

Host:  

Rabbit

Application:  

WB, ICC/IF

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-RS01771
Research Areas:  

Others

CA5A Human Pre-designed siRNA Set A contains three designed siRNAs for CA5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P790063
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CaV1; CaVeolin; Prev. CaV; BSCL3; CaVeolin 1, CaVeolae Protein, 22kDa; LCCNS; CaVeolin-1; VIP21; CaVeolin 1, CaVeolae Protein, 22kD; CGL3; Cell Growth-Inhibiting Protein 32; PPH3; Alternative Protein CaV1; CaVeolin 1; MSTP085
Species:  
Human
Source:  
E. coli Cell-free
loading...
    loading...
Cat. No.: HY-N12768
CAS No.: 37720-87-9
Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don
(Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain .
loading...
    loading...
Cat. No.: HY-111828R
CAS No.: 953778-63-7
Research Areas:  

Neurological Disease

TTA-A2 (Standard) is the analytical standard of TTA-A2 (HY-111828). This product is intended for research and analytical applications. TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .
loading...
    loading...
Cat. No.: HY-P810410
Synonyms: CaV3, CaV3_HUMAN, CaVeolin 3, CaVeolin-3, LGMD1C, LQT9, M-CaVeolin, MGC126100, MGC126101, MGC126129

Host:  

Rabbit

Application:  

WB, IP, IHC-P

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-181755
CAS No.: 109621-29-6
Target:  

NO Synthase

Research Areas:  

Inflammation/Immunology

Phenylaminojuglone AJ-2 is a nitric oxide synthase inhibitor that interacts with soluble guanylate cyclase, β-adrenergic receptor, CaV1.2 calcium channel, KV channel and KCa channel. Phenylaminojuglone AJ-2 blocks extracellular Ca 2+ influx, regulates the activity of the NO?sGC?cGMP signaling pathway, and inhibits pharmacologic and electromechanical contractions of smooth muscle. Phenylaminojuglone AJ-2 is applicable to studies related to intestinal spasm .
loading...
    loading...
Cat. No.: HY-115548
CAS No.: 1443735-02-1
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

ROMK-IN-1 is an orally active inhibitor of ROMK (Kir1.1) with an IC50 of 0.073 μM. ROMK-IN-1 exhibits no activity against Kir2.1, Kir4.1, Kir7.1, Nav1.5, Cav1.2, as well as the enzymes CYP3A4, CYP2D6, and CYP2C9. ROMK-IN-1 can be used in research related to hypertension .
loading...
    loading...
Cat. No.: HY-FLB0166
CAS No.: 50-81-7
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

Vitamin C solution is mainly composed of L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
loading...
    loading...